Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01700192
Other study ID # P05607
Secondary ID MK-8237-001
Status Completed
Phase Phase 3
First received October 2, 2012
Last updated September 14, 2017
Start date January 2013
Est. completion date April 2015

Study information

Verified date September 2017
Source ALK-Abelló A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.

The primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).


Recruitment information / eligibility

Status Completed
Enrollment 1482
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria:

- History of AR/ARC to house dust of 1 year duration or more (with or without asthma)

- If female of childbearing potential, has a negative urine pregnancy test at Screening and agrees to remain abstinent or use (or have their partner use) an acceptable method of birth control within the projected duration of the study

- Able to read, understand and complete questionnaires and diaries

Exclusion Criteria:

- Clinically relevant history of symptomatic ARC caused by animal dander, molds and/or cockroach (e.g. present in the home, job, daycare, etc.) or other perennial allergen

- History of symptomatic seasonal ARC and/or asthma due to an allergen to which the participant is sensitized and regularly exposed

- Nasal condition that could confound the efficacy or safety assessments (e.g., nasal polyposis)

- Received an immunosuppressive treatment within 3 months prior to screening

- Unstable or severe asthma, or has experienced a life-threatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids (but allowing short-acting beta agonists [SABAs]) at any time within 3 months prior to screening

- Asthma requiring high-dose inhaled corticosteroids (ICS) within 6 months prior to screening

- History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, unknown cause or inhalant allergen

- History of chronic urticaria and/or angioedema within 2 years prior to screening

- History of chronic sinusitis during 2 years prior to screening

- Pregnant, breastfeeding, or expecting to conceive within the projected duration of the study

- Previous immunotherapy treatment with any HDM allergen for more than 1 month within 5 years prior to screening

- Previous exposure to MK-8237

- Receiving ongoing treatment with any specific immunotherapy at screening

- Known history of allergy, hypersensitivity or intolerance to investigational medicinal products (except for D. pteronyssinus and/or D. farinae), rescue medications or self-injectable epinephrine

- Unable to meet medication washout requirements prior to screening

- Unable or unwilling to comply with the use of self-injectable epinephrine

- Business or personal relationship with investigational site personnel or Sponsor who is directly involved with the conduct of the study

- Likely to travel for extended periods of time during the efficacy assessment period

- Participating in a different investigational study at any site during this study

Study Design


Intervention

Biological:
MK-8237 tablets
MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
Placebo tablets
Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
Drug:
Rescue Medication: Self-Injectable Epinephrine
Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
Rescue Medication: Loratadine tablets
Loratadine tablet 10 mg administered orally as needed for rescue medication.
Rescue Medication: Olopatadine ophthalmic drops
Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
Rescue Medication: Mometasone furoate nasal spray
Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
ALK-Abelló A/S Merck Sharp & Dohme Corp.

References & Publications (1)

Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allerg — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment The TCRS is the sum of the rhinitis Daily Symptom Score (DSS; range: 0 to 12) and the rhinitis Daily Medication Score (DMS; range: 0 to 12); the total possible TCRS ranges from 0 to 24 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment. Last 8 weeks of treatment (Weeks 44 to 52)
Primary Number of Participants Who Experience At Least One Adverse Event (AE) An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Up to 54 weeks
Primary Number of Participants Who Discontinue Study Drug Due to an AE An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Up to 52 weeks
Secondary Average Rhinitis Daily Symptom Score (Rhinitis DSS) During Last 8 Weeks of Treatment The Rhinitis DSS ranges from a score of 0 to 12 (higher scores indicative of greater symptom severity). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment. Last 8 weeks of treatment (Weeks 44 to 52)
Secondary Average Rhinitis Daily Medication Score (Rhinitis DMS) During Last 8 Weeks of Treatment The Rhinitis DMS ranges from a score of 0 to 12 (higher scores indicative of greater symptomatic medication use). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment. Last 8 weeks of treatment (Weeks 44 to 52)
Secondary Average Total Combined Rhinoconjunctivitis Score (TCS) During Last 8 Weeks of Treatment The TCS is the sum of the rhinoconjunctivitis DSS (rhinitis DSS and conjunctivitis DSS; range: 0 to 18) and the rhinoconjunctivitis DMS (rhinitis DMS and conjunctivitis DMS; range: 0 to 20); the total possible TCS ranges from 0 to 38 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment. Last 8 weeks of treatment (Weeks 44 to 52)
Secondary Average Allergic Rhinitis/Rhinoconjunctivitis Symptoms Assessed by Visual Analogue Scale (VAS) During Last 8 Weeks of Treatment Participants indicated the severity of symptoms in the past week on a VAS with a score range of 0 ("no symptoms") to 100 ("severe symptoms"). Symptoms were assessed during 2 clinic visits occurring during the final 8 weeks of treatment (VAS score reflects the mean of 2 scores). Last 8 weeks of treatment (Weeks 44 to 52)
See also
  Status Clinical Trial Phase
Completed NCT02443805 - Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR Phase 3
Completed NCT01231464 - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis Phase 3
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT00224523 - Long Term Safety Of GW685698X Via Nasal Biopsy Phase 3
Completed NCT00658918 - To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405) Phase 3
Completed NCT00404586 - Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber Phase 1
Withdrawn NCT02988778 - Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis Phase 3
Completed NCT00988247 - Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis Phase 3
Completed NCT01678807 - Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008) Phase 1
Completed NCT01644617 - A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627) Phase 2
Completed NCT01216384 - Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers Phase 1
Completed NCT00848965 - A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber Phase 4
Completed NCT00092118 - The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265) Phase 3
Completed NCT00839189 - Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults Phase 1
Completed NCT00570492 - Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study. Phase 4
Completed NCT00806754 - Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490) Phase 4
Recruiting NCT00153595 - EWO1 in Persistent Allergic Rhinitis Patients Phase 2/Phase 3
Completed NCT00132925 - An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis Phase 3
Completed NCT02498509 - Clinical Trial to Evaluate the Efficacy and Safety of CKD-342 Phase 3
Completed NCT01134705 - Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis) Phase 3